Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license agreement with Shire AG, to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads. Arrowhead will receive research funding and could be eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales. Additional financial terms of the agreement were not disclosed.

Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics

Pasadena, CA | Posted on December 18th, 2012

"Shire's expertise in developing innovative medicines for rare diseases makes them an ideal partner for Arrowhead as we advance our platform of human-derived Homing Peptides," said Dr. Chris Anzalone, President and Chief Executive Officer of Arrowhead. "Our library of over 42,000 unique targeting peptide sequences can potentially be used to deliver therapeutics to more than 30 tissue types while avoiding non-specific uptake. We view this collaboration as a significant validation of our technology and discovery capabilities. Moreover, this agreement underscores our strategy of building value by developing an internal pipeline of PDCs and RNAi therapeutics and by working with partners to improve their proprietary medicines with our peptide targeting."

"With this novel platform technology, Shire has the potential to move into a wider range of orphan diseases," said Dr. Phil Vickers, Head of R&D at Shire HGT. "Our goal is to develop treatments that profoundly change the lives of patients with a variety of rare life-altering and life-threatening conditions. This collaboration with Arrowhead is evidence of Shire's commitment to patients with rare diseases and our intent to work with the best partners to achieve this."

Under the agreement, Arrowhead will identify peptides that selectively bind and internalize in an undisclosed tissue type and that are capable of delivering a therapeutic payload to that tissue. The company will receive funding for its internal and external research program-related costs and Shire will have an option to obtain an exclusive license to develop and commercialize a therapeutic agent targeted by the designated peptides and be responsible for clinical development and commercialization of products arising from the collaboration.

About Homing Peptides

Arrowhead's Homing Peptides comprise the world's largest library of human-derived peptide sequences that have been shown to localize to specific tissues in the human body. This platform enables the creation of guided therapeutics that specifically target tissues of interest while sparing off-target issues. The vast and growing proprietary library of Homing Peptides and numerous novel cell surface targets provide Arrowhead with building blocks for its own internal pipeline of drug candidates as well as opportunities to out-license or collaborate with partners. Our identification and screening directly in human patients, under strict ethical guidelines, has discovered peptide sequences that efficiently target known receptors, as well as novel, tissue specific receptors. Importantly, the platform enriches for receptors that rapidly internalize the peptide sequence and its associated payload.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone
CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

High-speed FM-AFM and simulation reveal atomistic dissolution processes of calcite in water July 28th, 2017

Atomic movies may help explain why perovskite solar cells are more efficient: SLAC's ultrafast 'electron camera' captures surprising atomic motions in these next-generation materials July 28th, 2017

Triple-layer catalyst does double duty: Rice, University of Houston produce robust catalyst to split water into hydrogen, oxygen July 28th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Shining rings: A new material emits white light when exposed to electricity: New synthetic approach could spark development of other dynamic materials July 24th, 2017

Scientists announce the quest for high-index materials: All-dielectric nanophotonics: The quest for better materials and fabrication techniques July 22nd, 2017

Announcements

High-speed FM-AFM and simulation reveal atomistic dissolution processes of calcite in water July 28th, 2017

Atomic movies may help explain why perovskite solar cells are more efficient: SLAC's ultrafast 'electron camera' captures surprising atomic motions in these next-generation materials July 28th, 2017

Triple-layer catalyst does double duty: Rice, University of Houston produce robust catalyst to split water into hydrogen, oxygen July 28th, 2017

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Patents/IP/Tech Transfer/Licensing

Argonne National Laboratory’s Continuous ALD Technology Licensed Exclusively to Forge Nano July 7th, 2017

Aculon Expands NanoProof® Product Line for Electronics Waterproofing Technology: With growing market opportunities Aculon Launches NanoProof® 8 with Push Through Connectivity™ and NanoProof® DAB a syringe application May 30th, 2017

NREL’s Advanced Atomic Layer Deposition Enables Lithium-Ion Battery Technology: May 10th, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Alliances/Trade associations/Partnerships/Distributorships

GLOBALFOUNDRIES and VeriSilicon To Enable Single-Chip Solution for Next-Gen IoT Networks: Integrated solution leverages GF’s 22FDX® technology to decrease power, area, and cost for NB-IoT and LTE-M applications July 14th, 2017

Advanced Nanomechanical Characterization Centre Open in India: Nanomechanics, Inc. announces the establishment of the joint technology development center in Hyderabad, India July 5th, 2017

U.S. Air Force Research Lab Taps IBM to Build Brain-Inspired AI Supercomputing System: Equal to 64 million neurons, new neurosynaptic supercomputing system will power complex AI tasks at unprecedented speed and energy efficiency June 23rd, 2017

Cambridge Nanotherm partners with Inabata for global sales and distribution June 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project